Details of the Drug

General Information of Drug (ID: DMRBMAU)

Drug Name
Mycophenolic acid
Synonyms
Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [2]
Interstitial cystitis GC00.3 Approved [3]
Large granular lymphocytic leukemia 2A90.1 Approved [2]
Leukemia N.A. Approved [4]
Lupus nephritis 4A40.0Y Approved [5]
MALT lymphoma N.A. Approved [2]
Myeloid leukaemia 2B33.1 Approved [6]
Myeloproliferative neoplasm 2A20 Approved [7]
Nodal marginal zone lymphoma 2A85.0 Approved [2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [2]
Recurrent adult burkitt lymphoma 2A85.6 Approved [2]
Small intestine lymphoma N.A. Approved [2]
Splenic marginal zone lymphoma N.A. Approved [2]
Systemic lupus erythematosus 4A40.0 Approved [8]
Testicular lymphoma N.A. Approved [2]
Classic Hodgkin lymphoma N.A. Investigative [9]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [10]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [11]
⏷ Show the Full List of Indication(s)
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 320.3
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C17H20O6
IUPAC Name
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
Canonical SMILES
CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O
InChI
HPNSFSBZBAHARI-RUDMXATFSA-N
InChIKey
1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
Cross-matching ID
PubChem CID
446541
ChEBI ID
CHEBI:168396
CAS Number
483-60-3
DrugBank ID
DB01024
INTEDE ID
DR1119
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MERS-CoV papain-like proteinase (PL-PRO) TTYJOLE R1AB_CVEMC (854-2740) Inhibitor [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [12]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mycophenolic acid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Mycophenolic acid due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [15]
Clindamycin DM15HL8 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Clindamycin. Acne vulgaris [ED80] [16]
Cefuroxime DMSIMD8 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefuroxime. Acute bronchitis [CA42] [16]
Paromomycin DM1AGXN Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Paromomycin. Amoebiasis [1A36] [16]
Cefamandole DMNEXZF Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefamandole. Anaerobic bacterial infection [1A00-1A09] [16]
Aminophylline DML2NIB Minor Increased plasma concentration of Mycophenolic acid and Aminophylline due to competitive binding of plasma proteins. Asthma [CA23] [16]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Mycophenolic acid and Roflumilast. Asthma [CA23] [17]
Cefotetan DM07TX3 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefotetan. Bacterial infection [1A00-1C4Z] [16]
Ofloxacin DM0VQN3 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [16]
Oritavancin DM28D05 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Oritavancin. Bacterial infection [1A00-1C4Z] [16]
Kanamycin DM2DMPO Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Kanamycin. Bacterial infection [1A00-1C4Z] [16]
Ceftizoxime DM3VOGS Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftizoxime. Bacterial infection [1A00-1C4Z] [16]
Dalfopristin DM4LTKV Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Dalfopristin. Bacterial infection [1A00-1C4Z] [16]
Clarithromycin DM4M1SG Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Clarithromycin. Bacterial infection [1A00-1C4Z] [16]
Ticarcillin DM4ME02 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Ticarcillin. Bacterial infection [1A00-1C4Z] [16]
Cefoperazone DM53PV8 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefoperazone. Bacterial infection [1A00-1C4Z] [16]
Cefprozil DM7DSYP Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefprozil. Bacterial infection [1A00-1C4Z] [16]
Sparfloxacin DMB4HCT Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [16]
Ceftriaxone DMCEW64 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftriaxone. Bacterial infection [1A00-1C4Z] [16]
Streptomycin DME1LQN Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Streptomycin. Bacterial infection [1A00-1C4Z] [16]
Dalbavancin DMGMNH3 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Dalbavancin. Bacterial infection [1A00-1C4Z] [16]
Gemifloxacin DMHT34O Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [16]
Cefepime DMHVWIK Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefepime. Bacterial infection [1A00-1C4Z] [16]
Imipenem DMI9FBP Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Imipenem. Bacterial infection [1A00-1C4Z] [16]
Meticillin DMIKHN0 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Meticillin. Bacterial infection [1A00-1C4Z] [16]
Norfloxacin DMIZ6W2 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [16]
ABT-492 DMJFD2I Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by ABT-492. Bacterial infection [1A00-1C4Z] [16]
Cefpodoxime DMJUNY5 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [16]
Cefadroxil DMMC345 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefadroxil. Bacterial infection [1A00-1C4Z] [16]
Bacampicillin DMP54C7 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [16]
Cefazolin DMPDYFR Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefazolin. Bacterial infection [1A00-1C4Z] [16]
Novobiocin DMRFWGK Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Novobiocin. Bacterial infection [1A00-1C4Z] [16]
Levofloxacin DMS60RB Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [16]
Cefditoren DMSUVM1 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefditoren. Bacterial infection [1A00-1C4Z] [16]
Cefonicid DMTX2BH Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefonicid. Bacterial infection [1A00-1C4Z] [16]
Cefradine DMUNSWV Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefradine. Bacterial infection [1A00-1C4Z] [16]
Cloxacillin DMUTL7O Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cloxacillin. Bacterial infection [1A00-1C4Z] [16]
Amoxicillin DMUYNEI Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Amoxicillin. Bacterial infection [1A00-1C4Z] [16]
Troleandomycin DMUZNIG Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Troleandomycin. Bacterial infection [1A00-1C4Z] [16]
Cefoxitin DMY8NC4 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefoxitin. Bacterial infection [1A00-1C4Z] [16]
Ceftibuten DMWV2AG Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftibuten. Bronchitis [CA20] [16]
Oxtriphylline DMLHSE3 Minor Increased plasma concentration of Mycophenolic acid and Oxtriphylline due to competitive binding of plasma proteins. Cough [MD12] [16]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Mycophenolic acid due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [15]
Benzylpenicillin DMS9503 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Benzylpenicillin. Discovery agent [N.A.] [16]
Fosphenytoin DMOX3LB Minor Increased plasma concentration of Mycophenolic acid and Fosphenytoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [16]
Lincomycin DMVTHER Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Lincomycin. Gram-positive bacterial infection [1B74-1F40] [16]
Rifampin DMA8J1G Major Increased metabolism of Mycophenolic acid caused by Rifampin mediated induction of UGT. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Mycophenolic acid and Teriflunomide. Hyper-lipoproteinaemia [5C80] [18]
TP-434 DM5A31S Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by TP-434. Infectious gastroenteritis/colitis [1A40] [16]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Mycophenolic acid and Denosumab. Low bone mass disorder [FB83] [19]
PF-06463922 DMKM7EW Moderate Increased metabolism of Mycophenolic acid caused by PF-06463922 mediated induction of UGT. Lung cancer [2C25] [20]
Sulphadoxine DMZI2UF Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Sulphadoxine. Malaria [1F40-1F45] [16]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Mycophenolic acid due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [21]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Mycophenolic acid and Tecfidera. Multiple sclerosis [8A40] [22]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Mycophenolic acid and Siponimod. Multiple sclerosis [8A40] [20]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Mycophenolic acid and Fingolimod. Multiple sclerosis [8A40] [23]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Mycophenolic acid and Ocrelizumab. Multiple sclerosis [8A40] [24]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Mycophenolic acid and Ozanimod. Multiple sclerosis [8A40] [17]
Gatifloxacin DMSL679 Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [16]
Colistimethate DMZ9BMU Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Colistimethate. Respiratory infection [CA07-CA4Z] [16]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Mycophenolic acid and Canakinumab. Rheumatoid arthritis [FA20] [25]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Mycophenolic acid and Rilonacept. Rheumatoid arthritis [FA20] [25]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Mycophenolic acid and Golimumab. Rheumatoid arthritis [FA20] [26]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Mycophenolic acid and Leflunomide. Rheumatoid arthritis [FA20] [18]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Mycophenolic acid when combined with Anthrax vaccine. Sepsis [1G40-1G41] [27]
Cephapirin DMV2JNY Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Cephapirin. Sepsis [1G40-1G41] [16]
Tedizolid DMG2SKR Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [16]
Pitolisant DM8RFNJ Moderate Increased metabolism of Mycophenolic acid caused by Pitolisant mediated induction of UGT. Somnolence [MG42] [17]
Doripenem DM9UCJK Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Doripenem. Urinary tract infection [GC08] [16]
Plazomicin DMKMBES Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Plazomicin. Urinary tract infection [GC08] [16]
Secnidazole DMJ18YL Moderate Altered absorption of Mycophenolic acid due to GI flora changes caused by Secnidazole. Vaginal discharge [MF3A] [16]
⏷ Show the Full List of 71 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol. 2011 Mar;185(3):901-6.
4 New conjugates of mycophenolic acid and their antiproliferative activity. J Asian Nat Prod Res. 2016 Nov;18(11):1057-62.
5 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
6 Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. Leuk Res Treatment. 2012;2012:861301.
7 Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1407-1415.
8 Systemic Lupus Erythematosus Management in Pregnancy. Int J Womens Health. 2022 Feb 15;14:199-211.
9 Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database. Pathol Res Pract. 2018 Nov;214(11):1854-1867.
10 Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020 Mar 27;14:1022.
11 SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
12 C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
13 Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007 Jun 30;74(1):161-8.
14 Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
15 Bullingham R, Shah J, Goldblum R, Schiff M "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol 41 (1996): 513-6. [PMID: 8799515]
16 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
19 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
20 Cerner Multum, Inc. "Australian Product Information.".
21 Canadian Pharmacists Association.
22 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
23 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
24 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
25 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
26 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
27 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]